88 related articles for article (PubMed ID: 11122832)
1. Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.
Rashidi A; Walter RB; Tallman MS; Appelbaum FR; DiPersio JF
Blood; 2016 Aug; 128(6):763-73. PubMed ID: 27354720
[No Abstract] [Full Text] [Related]
2. Antibody immunotherapy for leukemia.
Jurcic JG
Curr Oncol Rep; 2000 Mar; 2(2):114-22. PubMed ID: 11122832
[TBL] [Abstract][Full Text] [Related]
3. Antibody-based treatment of acute myeloid leukaemia.
Mulford DA; Jurcic JG
Expert Opin Biol Ther; 2004 Jan; 4(1):95-105. PubMed ID: 14680472
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for acute myeloid leukemia.
Jurcic JG
Curr Oncol Rep; 2005 Sep; 7(5):339-46. PubMed ID: 16091194
[TBL] [Abstract][Full Text] [Related]
5. Antibody therapy in acute myeloid leukemia: current status and future directions.
Burke JM; Jurcic JG
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S12-8. PubMed ID: 11970765
[TBL] [Abstract][Full Text] [Related]
6. Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches.
Jurcic JG; Cathcart K; Pinilla-Ibarz J; Scheinberg DA
Curr Opin Hematol; 2000 Jul; 7(4):247-54. PubMed ID: 10882181
[TBL] [Abstract][Full Text] [Related]
7. Antibody therapy of acute myelogenous leukemia.
Jurcic JG
Cancer Biother Radiopharm; 2000 Aug; 15(4):319-26. PubMed ID: 11041016
[TBL] [Abstract][Full Text] [Related]
8. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
Demidem A; Lam T; Alas S; Hariharan K; Hanna N; Bonavida B
Cancer Biother Radiopharm; 1997 Jun; 12(3):177-86. PubMed ID: 10851464
[TBL] [Abstract][Full Text] [Related]
9. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
Jurcic JG; DeBlasio T; Dumont L; Yao TJ; Scheinberg DA
Clin Cancer Res; 2000 Feb; 6(2):372-80. PubMed ID: 10690513
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.
Sgouros G; Ballangrud AM; Jurcic JG; McDevitt MR; Humm JL; Erdi YE; Mehta BM; Finn RD; Larson SM; Scheinberg DA
J Nucl Med; 1999 Nov; 40(11):1935-46. PubMed ID: 10565792
[TBL] [Abstract][Full Text] [Related]
11. Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
Kreitman RJ; Wilson WH; Robbins D; Margulies I; Stetler-Stevenson M; Waldmann TA; Pastan I
Blood; 1999 Nov; 94(10):3340-8. PubMed ID: 10552943
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
13. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA
J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
